J
Joseph A. Galanko
Researcher at University of North Carolina at Chapel Hill
Publications - 223
Citations - 13879
Joseph A. Galanko is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Population & Odds ratio. The author has an hindex of 61, co-authored 210 publications receiving 12231 citations.
Papers
More filters
Journal ArticleDOI
Radiofrequency Ablation in Barrett's Esophagus with Dysplasia
Nicholas J. Shaheen,Prateek Sharma,Bergein F. Overholt,Herbert C. Wolfsen,Richard E. Sampliner,Kenneth K. Wang,Joseph A. Galanko,Mary P. Bronner,John R. Goldblum,Ana E. Bennett,Blair A. Jobe,Glenn M. Eisen,M. Brian Fennerty,John G. Hunter,David E. Fleischer,Virender K. Sharma,Robert H. Hawes,Brenda J. Hoffman,Richard I. Rothstein,Stuart R. Gordon,Hiroshi Mashimo,Kenneth J. Chang,V. Raman Muthusamy,Steven A. Edmundowicz,Stuart J. Spechler,Ali A. Siddiqui,Rhonda F. Souza,Anthony Infantolino,Gary W. Falk,Michael B. Kimmey,Ryan D. Madanick,Amitabh Chak,Charles J. Lightdale +32 more
TL;DR: In patients with dysplastic Barrett's esophagus, radiofrequency ablation was associated with a high rate of complete eradication of both dysplasia and intestinal metaplasia, and a reduced risk of disease progression.
Journal ArticleDOI
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.
Anne F. Peery,Seth D. Crockett,Caitlin C. Murphy,Jennifer L. Lund,Evan S. Dellon,J. Lucas Williams,Elizabeth T. Jensen,Nicholas J. Shaheen,Alfred S. Barritt,Sarah R. Lieber,Bharati Kochar,Edward L. Barnes,Y. Claire Fan,Virginia Pate,Joseph A. Galanko,Todd H. Baron,Robert S. Sandler +16 more
TL;DR: GI diseases contribute substantially to health care use in the United States and total expenditures for GI diseases are $135.9 billion annually-greater than for other common diseases.
Journal ArticleDOI
Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.
Michael D. Kappelman,Sheryl L. Rifas-Shiman,Carol Q. Porter,Daniel A. Ollendorf,Robert S. Sandler,Joseph A. Galanko,Jonathan A. Finkelstein +6 more
TL;DR: This study demonstrates a substantial economic burden of IBD and can be used to inform health policy as well as identify sociodemographic factors influencing these costs.
Journal ArticleDOI
Liver transplantation for acute liver failure from drug induced liver injury in the United States
TL;DR: Four drugs were implicated in 42% of patients undergoing liver transplants for acute liver failure due to drugs other than APAP, and the increased frequency of African‐American women undergoing liver transplantation for non‐APAP drug induced liver injury warrants further study.
CLINICAL—ALIMENTARY TRACT Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia
Nicholas J. Shaheen,Bergein F. Overholt,Richard E. Sampliner,Herbert C. Wolfsen,Kenneth K. Wang,David E. Fleischer,Virender K. Sharma,Glenn M. Eisen,M. Brian Fennerty,John G. Hunter,Mary P. Bronner,John R. Goldblum,Ana E. Bennett,Hiroshi Mashimo,Richard I. Rothstein,Stuart R. Gordon,Steven A. Edmundowicz,Ryan D. Madanick,Anne F. Peery,V. Raman Muthusamy,Kenneth J. Chang,Michael B. Kimmey,Stuart J. Spechler,Ali Ahmed Siddiqui,Rhonda F. Souza,Anthony Infantolino,John A. Dumot,Gary W. Falk,Joseph A. Galanko,Blair A. Jobe,Robert H. Hawes,Brenda J. Hoffman,Prateek Sharma,Amitabh Chak,Charles J Lightdale +34 more
TL;DR: In this paper, a randomized trial of 127 patients with dysplastic Barrett's esophagus (BE) showed that radiofrequency ablation (RFA) therapy has an acceptable safety profile, is durable, and is associated with a low rate of disease progression, for up to 3 years.